HDAC9 and breast carcinoma: VPA is a class I and II HDAC inhibitor approved for the treatment of breast cancer, myelodysplastic syndrome, acute myeloid leukemia, and spinal muscular atrophy in patients (NCT01900730, NCT00374075, NCT00326170).